Form 4: Versant Funds Reduce LENZ Therapeutics Holdings

Versant Venture Capital VI, L.P. and affiliated entities reported multiple sales of LENZ Therapeutics, Inc. common stock on September 30, 2025, reducing their beneficial ownership.

Summary

• Versant Venture Capital VI, L.P., along with affiliated entities Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., and Versant Ventures VII GP-GP, LLC, are the reporting persons.
• The reporting persons are identified as both a Director and a 10% Owner of LENZ Therapeutics, Inc. (LENZ).
• On September 30, 2025, a total of 224,974 shares of LENZ Therapeutics, Inc. common stock were sold across multiple transactions.
• The sales occurred at weighted average prices of $45.3547, $46.4068, and $47.0133 per share.
• Following these transactions, Versant Venture Capital VI, L.P. directly holds 1,050,599 shares.
• Versant Venture Capital VII, L.P. indirectly holds 764,127 shares.
• Versant Vantage II, L.P. indirectly holds 842,162 shares.

Sentiment

Score: 3

Explanation: The filing reports significant insider selling by a major venture capital firm and director, which is typically viewed negatively by the market as it may indicate a lack of future confidence or a strategic divestment.

Negatives

• Significant insider selling by a major institutional investor and director, Versant Venture Capital, and its affiliated entities.
• A total of 224,974 shares of LENZ Therapeutics, Inc. common stock were sold, representing a notable reduction in their holdings.
• Sales occurred at various price points ranging from $45.00 to $47.02, indicating a divestment strategy over a price range.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential negative sentiment and downward pressure on stock price due to significant insider selling by a major investor and director.

Key Dates

Recommendation

The significant sale of shares by a major institutional investor and director, Versant Venture Capital, suggests a potential lack of confidence in the company's near-term prospects or a strategic portfolio rebalancing. This insider selling could exert downward pressure on the stock price and warrants caution for investors.

Keywords

LENZ, Versant, Form 4, insider selling, beneficial ownership, venture capital, stock sale, LENZ Therapeutics